FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089595930> ?p ?o ?g. }

• W3089595930 abstract "Background Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that contributes to immunoregulation at many levels, including suppressing effector T cells and inducing/activating regulatory T cells. Thus far, several therapeutic approaches to target IDO1 enzymatic activity have shown promise in preclinical models, however, results from the first major clinical trial were disappointing. The present study seeks to provide preclinical PoC data for the conceptually unique idea of developing an IDO1-targeted vaccine based on our earlier findings that humans exhibit intrinsic T cell reactivity against IDO1 epitopes 1 suggesting the existence of a T cell-mediated, counter-regulatory mechanism directed against cells that express IDO1. Materials and Methods IDO1-derived peptide vaccines were identified by measurement of vaccine-induced ex vivo response (IFNγ ELISpot) and demonstration of anti-tumor responses in CT26 tumor-bearing mice. To understand the vaccine’s mode of action, resected tumors were analyzed by immunofluorescence microscopy and flow cytometry. Results The CT26 colon carcinoma model was selected for these studies based on evidence of high levels of IDO1 expression and responsiveness to IDO1 inhibition reported for these tumors. In silico -predicted H2 d MHC class I and II-restricted IDO1 peptide sequences were tested and vaccine candidates were chosen after confirming ex vivo response and anti-tumor response in CT26. Therapeutic treatment of established CT26 tumors with MHC class I- and II-directed, IDO1-derived peptide vaccines elicited anti-tumor responses when administered alone, and the effect was further pronounced when combined, suggesting distinct mechanisms of action. In addition, a combination of IDO1 vaccine with anti-PD-1 antibody produced a combinatorial anti-tumor response beyond what was achieved with either agent alone. Consistent with this observation, adoptive transfer of isolated CD8+ T cells from class I and CD4+ T cells from class II peptide-vaccinated responder mice delayed tumor growth in treatment naïve mice. The class II-directed response was completely IDO1-dependent while the class I-directed response included an IDO1-independent component indicative of antigen spread. Examination into the tumors in vaccinated mice indicated that IDO1 vaccine treatment exerts its effect by selective reduction of IDO1 expression in the tumor microenvironment and concomitant expansion of activated CD4 + and CD8 + T cells. Conclusions As noted in humans, our data demonstrate that IDO1 is immunogenic in mice confirming that this endogenous protein is excluded from normal tolerance mechanisms. The observed immunotherapeutic efficacy of IDO1 peptide vaccines on their own and in combination with anti-PD-1 antibody support the rationale for ongoing clinical development of IDO1 peptide vaccine-based therapy. Future studies include further differentiation of the vaccine platform against other IDO1-targeting approaches, as well as decoding the underlying mechanism of cooperativity between anti-PD-1 antibody and IDO1 peptide vaccines. Reference Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2011; 117 (7): 2200–10 Disclosure Information S. Dey: None. E. Sutanto-Ward: None. K.L. Kopp: A. Employment (full or part-time); Significant; IO Biotech. J.B. DuHadaway: None. A. Mondal: None. I. Lecoq: A. Employment (full or part-time); Significant; IO Biotech. M. Zocca: A. Employment (full or part-time); Significant; IO Biotech. M.H. Andersen: A. Employment (full or part-time); Significant; IO Biotech. A.W. Pedersen: A. Employment (full or part-time); Significant; IO Biotech. A.J. Muller: F. Consultant/Advisory Board; Modest; IO Biotech." @default.
• W3089595930 created "2020-10-08" @default.
• W3089595930 creator A5008904835 @default.
• W3089595930 creator A5017231989 @default.
• W3089595930 creator A5025503934 @default.
• W3089595930 creator A5033586111 @default.
• W3089595930 creator A5035691910 @default.
• W3089595930 creator A5055947307 @default.
• W3089595930 creator A5057211669 @default.
• W3089595930 creator A5066825590 @default.
• W3089595930 creator A5077726380 @default.
• W3089595930 creator A5087182533 @default.
• W3089595930 date "2020-10-01" @default.
• W3089595930 modified "2023-09-26" @default.
• W3089595930 title "P04.03 Immune modulatory vaccine directed against IDO1-expressing immune cells elicits T cell-mediated anti-tumor immunity and enhances anti-PD1 responses" @default.
• W3089595930 doi "https://doi.org/10.1136/jitc-2020-itoc7.72" @default.
• W3089595930 hasPublicationYear "2020" @default.
• W3089595930 type Work @default.
• W3089595930 sameAs 3089595930 @default.
• W3089595930 citedByCount "0" @default.
• W3089595930 crossrefType "journal-article" @default.
• W3089595930 hasAuthorship W3089595930A5008904835 @default.
• W3089595930 hasAuthorship W3089595930A5017231989 @default.
• W3089595930 hasAuthorship W3089595930A5025503934 @default.
• W3089595930 hasAuthorship W3089595930A5033586111 @default.
• W3089595930 hasAuthorship W3089595930A5035691910 @default.
• W3089595930 hasAuthorship W3089595930A5055947307 @default.
• W3089595930 hasAuthorship W3089595930A5057211669 @default.
• W3089595930 hasAuthorship W3089595930A5066825590 @default.
• W3089595930 hasAuthorship W3089595930A5077726380 @default.
• W3089595930 hasAuthorship W3089595930A5087182533 @default.
• W3089595930 hasBestOaLocation W30895959301 @default.
• W3089595930 hasConcept C147483822 @default.
• W3089595930 hasConcept C150903083 @default.
• W3089595930 hasConcept C195616568 @default.
• W3089595930 hasConcept C203014093 @default.
• W3089595930 hasConcept C207001950 @default.
• W3089595930 hasConcept C207936829 @default.
• W3089595930 hasConcept C26291073 @default.
• W3089595930 hasConcept C2776090121 @default.
• W3089595930 hasConcept C2776789287 @default.
• W3089595930 hasConcept C2777701055 @default.
• W3089595930 hasConcept C2779053233 @default.
• W3089595930 hasConcept C502942594 @default.
• W3089595930 hasConcept C553184892 @default.
• W3089595930 hasConcept C71924100 @default.
• W3089595930 hasConcept C86803240 @default.
• W3089595930 hasConcept C8891405 @default.
• W3089595930 hasConceptScore W3089595930C147483822 @default.
• W3089595930 hasConceptScore W3089595930C150903083 @default.
• W3089595930 hasConceptScore W3089595930C195616568 @default.
• W3089595930 hasConceptScore W3089595930C203014093 @default.
• W3089595930 hasConceptScore W3089595930C207001950 @default.
• W3089595930 hasConceptScore W3089595930C207936829 @default.
• W3089595930 hasConceptScore W3089595930C26291073 @default.
• W3089595930 hasConceptScore W3089595930C2776090121 @default.
• W3089595930 hasConceptScore W3089595930C2776789287 @default.
• W3089595930 hasConceptScore W3089595930C2777701055 @default.
• W3089595930 hasConceptScore W3089595930C2779053233 @default.
• W3089595930 hasConceptScore W3089595930C502942594 @default.
• W3089595930 hasConceptScore W3089595930C553184892 @default.
• W3089595930 hasConceptScore W3089595930C71924100 @default.
• W3089595930 hasConceptScore W3089595930C86803240 @default.
• W3089595930 hasConceptScore W3089595930C8891405 @default.
• W3089595930 hasLocation W30895959301 @default.
• W3089595930 hasOpenAccess W3089595930 @default.
• W3089595930 hasPrimaryLocation W30895959301 @default.
• W3089595930 hasRelatedWork W10697072 @default.
• W3089595930 hasRelatedWork W10734638 @default.
• W3089595930 hasRelatedWork W11113079 @default.
• W3089595930 hasRelatedWork W13010074 @default.
• W3089595930 hasRelatedWork W14289313 @default.
• W3089595930 hasRelatedWork W2151330 @default.
• W3089595930 hasRelatedWork W2495403 @default.
• W3089595930 hasRelatedWork W2693788 @default.
• W3089595930 hasRelatedWork W5239270 @default.
• W3089595930 hasRelatedWork W8453341 @default.
• W3089595930 isParatext "false" @default.
• W3089595930 isRetracted "false" @default.
• W3089595930 magId "3089595930" @default.
• W3089595930 workType "article" @default.